PET imaging with 68Gallium-labelled ligand of prostate-specific membrane antigen (68Ga-HBED-PSMA) for staging of biochemical recurrent prostate cancer after radical prostatectomy.

Abstract

5023 Background: Staging of recurrent prostate cancer (PCa) after radical prostatectomy (RP) remains challenging especially at low PSA values. Prostate-specific membrane antigen (PSMA) shows increased expression on most PCa and might therefore be useful for detection of PCa lesions. Aim of this retrospective analysis of consecutive pts was to evaluate the detection rate of PET hybrid imaging using the PSMA inhibitor Glu-NH-CO-NH-Lys-(Ahx)-[(68)Ga(HBED-CC)] (68Ga-HBED-PSMA) in pts with biochemical recurrence (BCR) of PCa after RP. Methods: 332 consecutive pts with BCR of PCa after RP and a median PSA value of 1.7 ng/ml (range 0.2-63 ng/ml) were included in this analysis. After injection of 122±17 MBq 68Ga-HBED-PSMA-PET/CT or PET/MR was performed in 256 pts and 76 pts, respectively. One nuclear medicine physician and one radiologist reviewed imaging in consensus. Detection rates according to PSA value were determined. Results: In total, detection rates for 68Ga-HBED-PSMA-PET hybrid imaging were 96.0% (143/1...